<p>ImmunoPrecise Antibodies（納斯達克股票代碼：HYFT）將於 2025 年 12 月 15 日（星期一）發佈季度財報。以下是投資者在公告前的簡要概述。</p>
<p>分析師預計 ImmunoPrecise Antibodies 的 <strong>每股收益</strong>（EPS）為$-0.01。</p>
<p>ImmunoPrecise Antibodies 的投資者熱切期待公司的公告，希望能聽到超出預期的消息以及對下個季度的積極指引。</p>
<p>值得新投資者注意的是，股票價格往往受到未來預測的重大影響，而不僅僅是過去的表現。</p>
<h3>盈利記錄</h3>
<p>在上個季度，公司報告的每股收益低於預期$0.03，導致次日股價下跌 9.66%。</p>
<p>以下是 ImmunoPrecise Antibodies 的過去表現及其導致的價格變化：</p>
<table>
<thead>
<tr>
<th><strong>季度</strong></th>
<th align="right"><strong>2026 年第一季度</strong></th>
<th align="right"><strong>2025 年第四季度</strong></th>
<th align="right"><strong>2025 年第三季度</strong></th>
<th align="right"><strong>2025 年第二季度</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS 預估</strong></td>
<td align="right">-0.04</td>
<td align="right">-0.02</td>
<td align="right">-0.060</td>
<td align="right">-0.05</td>
</tr>
<tr>
<td><strong>EPS 實際</strong></td>
<td align="right">-0.07</td>
<td align="right">-0.04</td>
<td align="right">-0.014</td>
<td align="right">-0.07</td>
</tr>
<tr>
<td><strong>價格變化百分比</strong></td>
<td align="right">-10.00</td>
<td align="right">1.00</td>
<td align="right">-11.000</td>
<td align="right">-5.00</td>
</tr>
</tbody>
</table>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1765548046_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="eps graph" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1765548046_0.png"/></p>
<h3>ImmunoPrecise Antibodies 股票表現</h3>
<p>截至 12 月 11 日，ImmunoPrecise Antibodies 的股票交易價格為$1.87。在過去 52 周內，股票上漲了 334.88%。鑑於這些回報通常是積極的，長期股東在此次財報發佈前可能持樂觀態度。</p>
<p>要跟蹤 ImmunoPrecise Antibodies 的所有財報發佈，請訪問我們網站上的財報日曆。</p>
<p><em>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</em></p>

<p>ImmunoPrecise Antibodies（納斯達克代碼：HYFT）將於 2025 年 12 月 15 日發佈季度財報。分析師預計每股收益（EPS）為-0.01 美元。在上個季度，該公司每股收益未能達到預期，差距為 0.03 美元，導致股價下跌 9.66%。目前，股票交易價格為 1.87 美元，過去一年上漲了 334.88%。投資者對積極的指引和超出預期的業績抱有希望</p>

<p>ImmunoPrecise Antibodies (NASDAQ: HYFT) will release its quarterly earnings report on Monday, 2025-12-15. Here's a brief overview for investors ahead of the announcement.</p>
<div class="lb-trans"><p>ImmunoPrecise Antibodies（納斯達克股票代碼：HYFT）將於 2025 年 12 月 15 日（星期一）發佈季度財報。以下是投資者在公告前的簡要概述。</p>
</div><p>Analysts anticipate ImmunoPrecise Antibodies to report an <strong>earnings per share</strong> (EPS) of $-0.01.</p>
<div class="lb-trans"><p>分析師預計 ImmunoPrecise Antibodies 的 <strong>每股收益</strong>（EPS）為$-0.01。</p>
</div><p>Investors in ImmunoPrecise Antibodies are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<div class="lb-trans"><p>ImmunoPrecise Antibodies 的投資者熱切期待公司的公告，希望能聽到超出預期的消息以及對下個季度的積極指引。</p>
</div><p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<div class="lb-trans"><p>值得新投資者注意的是，股票價格往往受到未來預測的重大影響，而不僅僅是過去的表現。</p>
</div><h3>Earnings Track Record</h3>
<div class="lb-trans"><h3>盈利記錄</h3>
</div><p>During the last quarter, the company reported an EPS missed by $0.03, leading to a 9.66% drop in the share price on the subsequent day.</p>
<div class="lb-trans"><p>在上個季度，公司報告的每股收益低於預期$0.03，導致次日股價下跌 9.66%。</p>
</div><p>Here's a look at ImmunoPrecise Antibodies's past performance and the resulting price change:</p>
<div class="lb-trans"><p>以下是 ImmunoPrecise Antibodies 的過去表現及其導致的價格變化：</p>
</div><table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th align="right"><strong>Q1 2026</strong></th>
<th align="right"><strong>Q4 2025</strong></th>
<th align="right"><strong>Q3 2025</strong></th>
<th align="right"><strong>Q2 2025</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td align="right">-0.04</td>
<td align="right">-0.02</td>
<td align="right">-0.060</td>
<td align="right">-0.05</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td align="right">-0.07</td>
<td align="right">-0.04</td>
<td align="right">-0.014</td>
<td align="right">-0.07</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td align="right">-10.00</td>
<td align="right">1.00</td>
<td align="right">-11.000</td>
<td align="right">-5.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th><strong>季度</strong></th>
<th align="right"><strong>2026 年第一季度</strong></th>
<th align="right"><strong>2025 年第四季度</strong></th>
<th align="right"><strong>2025 年第三季度</strong></th>
<th align="right"><strong>2025 年第二季度</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS 預估</strong></td>
<td align="right">-0.04</td>
<td align="right">-0.02</td>
<td align="right">-0.060</td>
<td align="right">-0.05</td>
</tr>
<tr>
<td><strong>EPS 實際</strong></td>
<td align="right">-0.07</td>
<td align="right">-0.04</td>
<td align="right">-0.014</td>
<td align="right">-0.07</td>
</tr>
<tr>
<td><strong>價格變化百分比</strong></td>
<td align="right">-10.00</td>
<td align="right">1.00</td>
<td align="right">-11.000</td>
<td align="right">-5.00</td>
</tr>
</tbody>
</table>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1765548046_0.png" alt="eps graph" original-src="https://www.benzinga.com/files/images/story/2025/1765548046_0.png"/></p>
<h3>Performance of ImmunoPrecise Antibodies Shares</h3>
<div class="lb-trans"><h3>ImmunoPrecise Antibodies 股票表現</h3>
</div><p>Shares of ImmunoPrecise Antibodies were trading at $1.87 as of December 11. Over the last 52-week period, shares are up 334.88%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.</p>
<div class="lb-trans"><p>截至 12 月 11 日，ImmunoPrecise Antibodies 的股票交易價格為$1.87。在過去 52 周內，股票上漲了 334.88%。鑑於這些回報通常是積極的，長期股東在此次財報發佈前可能持樂觀態度。</p>
</div><p>To track all earnings releases for ImmunoPrecise Antibodies visit their earnings calendar on our site.</p>
<div class="lb-trans"><p>要跟蹤 ImmunoPrecise Antibodies 的所有財報發佈，請訪問我們網站上的財報日曆。</p>
</div><p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>
<div class="lb-trans"><p><em>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</em></p>
</div>

ImmunoPrecise Antibodies 的盈利前景